How Generalizable Is The Soloist-whf Trial In ‘Real World’ Patients With Diabetes Admitted With Heart Failure? Results From A Large Us Integrated Health System

Mario Enrico Canonico,Judith Hsia,Michael Szarek,Christopher P. Cannon,Marc P. Bonaca

DOI: https://doi.org/10.1016/j.cardfail.2023.10.268

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction In SOLOIST-WHF trial sotagliflozin, a sodium-glucose cotransporter 1/2 inhibitor, reduced total (first and subsequent) events of hospitalization for heart failure (HHF) or cardiovascular (CV) death by 33% among patients with type 2 diabetes mellitus (T2DM) and recent HHF. We compared a SOLOIST-like group versus a group not meeting trial criteria from a large, diverse health system including urban and rural patients on baseline characteristics, medical therapy, and survival. Hypothesis and Methods Patients in the University of Colorado health system TriNetX database for patients age 18-85 years with T2DM and HHF (either inpatient or emergency department encounter with a primary diagnosis of HF) managed with intravenous diuretics and without acute coronary syndrome or stroke within 3 months, advanced chronic kidney disease or end stage HF were classified as SOLOIST-like. All patients with T2DM+HHF who did not meet the remaining criteria were classified as not-SOLOIST-like. Baseline characteristics of two groups were compared by chi-square and t-test. 1-year KM survival was assessed among study groups. Results In 2022, 2,790 patients (50%) with HHF+T2DM were identified as SOLOIST-like versus 2,830 patients not-SOLOIST-like. The SOLOIST-like group was younger with higher body mass index and had a higher prevalence of HF with reduced ejection fraction compared to the not-SOLOIST-like group (62% vs 58%, p<0.001) (Table 1). Furthermore, SOLOIST-like patients were more often treated with mineralocorticoid receptor antagonist (38% vs 34%, p=0.004), as well as newer HF medications such as angiotensin receptor-neprilysin inhibitor - ARNI (9% vs 7%, p=0.004) or sodium-glucose cotransporter-2inhibitors - SGLT2i (25% vs 22%, p=0.005) despite the overall low prescription rate. No significant difference was found in 1-year KM survival analysis among the two study groups (HR 0.91; 95% CI 0.79-1.04,p=0.30) (Figure 1). Conclusion Our data suggest that the SOLOIST-WHF trial results are very generalizable to the real-world population. Encouragingly, 25% of patients are being treated with SGLT2i in 2022, but efforts are needed to improve this and adherence to all guideline-directed medical therapy, including ARNI and MRA.

cardiac & cardiovascular systems